<div id="readability-page-1"><div> Health-care companies rose as defensive-minded traders rotated into the sector, which is viewed as relatively evergreen. Precious metals had been the preferred safe haven during recent domestic and geopolitical instability. Traders abruptly fled those investments following the unveiling of former Federal Reserve governor Kevin Warsh as President Trump's Fed nominee. Warsh was a much more conventional and possibly less dovish choice than market participants had anticipated. Drug giant Eli Lilly unveiled plans to open a $3.5 billion plant to produce weight-loss drugs in Pennsylvania's Lehigh Valley, giving the region an economic shot in the arm. British drug maker AstraZeneca said it entered into a collaboration agreement with China's CSPC Pharmaceuticals to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs, in a deal potentially valued at billions of dollars. Pfizer and Merck rose ahead of earnings next week. Health insurers remained under pressure due to concerns about the Trump administration's proposed rates for Medicare reimbursement. <pre></pre> Write to Rob Curran at rob.curran@dowjones.com (END) Dow Jones Newswires January 30, 2026 17:46 ET (22:46 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

生物科技 ETF - VanEck Vectors

新诺威

IBBQ

医疗股因市场不稳定而受到交易者的关注而上涨。礼来宣布将在宾夕法尼亚州投资 35 亿美元建设减肥药工厂，而阿斯利康则与新诺威合作获得肥胖和糖尿病药物的权益。辉瑞和默克在即将公布的财报前实现了上涨，但健康保险公司面临特朗普政府提出的医疗保险报销率的压力

Health Care Up After Defensive Rotation — Health Care Roundup

- 医疗保健公司因交易者转向其为防御性投资而上涨。  
- Eli Lilly 在宾夕法尼亚州计划投资 35 亿美元建设减肥药工厂。  
- 阿斯利康与中国 CSPC 制药达成合作，寻求肥胖和糖尿病药物的权利。

MorningStar

Invesco Nasdaq Biotechnology ETF

医疗业 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

辉瑞

美国制药 ETF - iShares

基因改革 ETF - ARK

2 倍做多 LLY ETF - Direxion

2 倍做多 LLY ETF - Defiance

动态生物技术与基因组 ETF - Invesco

标普全球医疗股指数 ETF - iShares

礼来

医疗业 ETF - Vanguard

默克

在防御性轮换之后，医疗保健板块上涨——医疗保健综述